Wellington Management Group LLP Purchases New Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)

Wellington Management Group LLP acquired a new stake in Aura Biosciences, Inc. (NASDAQ:AURA) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 116,392 shares of the company’s stock, valued at approximately $1,037,000. Wellington Management Group LLP owned 0.23% of Aura Biosciences at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of AURA. American Century Companies Inc. bought a new stake in Aura Biosciences in the second quarter valued at approximately $119,000. SG Americas Securities LLC acquired a new stake in Aura Biosciences during the 3rd quarter valued at $169,000. Rhumbline Advisers increased its holdings in shares of Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Aura Biosciences by 14.6% in the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after purchasing an additional 8,194 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Aura Biosciences by 26.3% during the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after buying an additional 15,000 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on AURA. Scotiabank raised their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, BTIG Research upped their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Down 2.8 %

Aura Biosciences stock opened at $8.11 on Friday. The stock has a market cap of $405.10 million, a PE ratio of -4.69 and a beta of 0.26. Aura Biosciences, Inc. has a 12-month low of $6.63 and a 12-month high of $12.38. The business’s 50-day moving average price is $9.70 and its two-hundred day moving average price is $8.76.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. As a group, analysts expect that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Janet Jill Hopkins sold 11,822 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now directly owns 151,693 shares in the company, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. This represents a 15.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,081 shares of company stock valued at $891,353. 5.40% of the stock is currently owned by insiders.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.